

CURRICULUM VITAE

Informazioni personali

Nome e Cognome: **Gian Paolo Caviglia**

Data di nascita: 24/07/1982

Luogo di nascita: Torino, Italia

Cittadinanza: Italiana

E-mail: gianpaolo.caviglia@unito.it


gcaviglia3@cittadellasalute.to.it


caviglia.giampi@libero.it

Posizione attuale

Ricercatore a Tempo Determinato tipo A (SSD MED/46) presso il Laboratorio di Epatologia e Gastroenterologia Molecolare
Dipartimento di Scienze Mediche
Università degli Studi di Torino
Corso Dogliotti 14,
10126 Torino,
Italia

Identificativi

 **ORCID ID:** 0000-0002-0529-9481

 **Scopus ID:** 24491739500

 **Web of Sciences ID:** H-6076-2012

 **Publons ID:** 1194409

Indicatori bibliometrici (aggiornati al 25/03/2023)

h-index (Scopus): 25

Citazioni (Scopus): 1987

Articoli indicizzati (Scopus): 156

Formazione

Titoli di studio

- Diploma di Maturità Scientifica (Liceo Scientifico di Stato Ettore Majorana - Torino).
- Laurea Magistrale in Biologia dell'Ambiente e del Lavoro, Classe LM-6 - conseguita presso Università degli Studi di Torino, il 22/04/2009, votazione 108/110, discussione della tesi dal titolo "*Marcatori non invasivi di fibrosi epatica: Fibroscan, Acido ialuronico e Breath Test alla 13C-Aminopirina*".
- Abilitazione all'esercizio della Professione Biologo - presso Università degli Studi di Pavia, l'1/12/2010.
- Dottorato di Ricerca in Fisiopatologia Medica - conseguito presso Università degli Studi di Torino, l'11/02/2016, discussione della tesi dal titolo "*Valutazione di un profilo di microRNA circolanti come potenziali biomarcatori di carcinoma epatocellulare in pazienti con infezione cronica da HBV*".
- Abilitazione Scientifica Nazionale (ASN) alle funzioni di professore universitario di Seconda Fascia nel Settore Concorsuale 06/N1 - SCIENZE DELLE PROFESSIONI SANITARIE E DELLE TECNOLOGIE MEDICHE APPLICATE a decorrere dal 06/06/2022.

Altre esperienze formative e lavorative

- Giugno 2006 – Maggio 2007, Collaborazione Coordinata Continuativa per il progetto *“Patterns di espressione genica e influenza della variabilità virale del virus dell’epatite C (HCV) in pazienti con epatite cronica in terapia combinata con interferone e ribavirina”*, presso il Laboratorio di Fisiopatologia Epatica e Digestiva, Dipartimento di Medicina Interna, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Alessia Ciancio.
- Giugno 2007 – Dicembre 2007, vincitore di Borsa di Studio per il progetto *“Patterns di espressione genica e influenza della variabilità virale del virus dell’epatite C (HCV) in pazienti con epatite cronica in terapia combinata con interferone e ribavirina”*, presso il Laboratorio di Fisiopatologia Epatica e Digestiva, Dipartimento di Medicina Interna, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Alessia Ciancio.
- Maggio 2008 – Aprile 2009, vincitore di Borsa di Studio per il progetto *“Patterns di espressione genica e influenza della variabilità virale del virus dell’epatite C (HCV) in pazienti con epatite cronica in terapia combinata con interferone e ribavirina”*, presso il Laboratorio di Fisiopatologia Epatica e Digestiva, Dipartimento di Medicina Interna, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Alessia Ciancio.
- Giugno 2009 – Maggio 2011, vincitore di Borsa di Studio per il progetto *“Ruolo dell’infezione occulta da virus dell’epatite B (OBI) in pazienti con epatite cronica e cirrosi epatica HCV-correlata”*, presso il Laboratorio di Fisiopatologia Epatica e Digestiva, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Antonina Smedile.
- Agosto 2011 – Luglio 2016, vincitore di Assegno di Ricerca per il progetto *“Analisi di un profilo di micro-RNA nel siero di pazienti con epatocarcinoma HBV correlato”*, presso il Laboratorio di Fisiopatologia Epatica e Digestiva, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Antonina Smedile.
- Agosto 2016 – Luglio 2017, vincitore di Assegno di Ricerca per il progetto *“Fattori predittivi e bio-marcatore sierici nella sorveglianza dei pazienti con malattia epatica avanzata a rischio di epatocarcinoma”*, presso il Laboratorio di Epatologia e Gastroenterologia Molecolare, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Antonina Smedile.
- Agosto 2017 – Luglio 2018, vincitore di Assegno di Ricerca per il progetto *“Analisi dei livelli di replicazione del virus dell’epatite C (HCV) nel fegato di pazienti trapiantati per cirrosi con epatocarcinoma dopo terapia con antivirali ad azione diretta (DAAs)”*, presso il Laboratorio di Epatologia e Gastroenterologia Molecolare, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Antonina Smedile/Prof.ssa Elisabetta Bugianesi.
- Agosto 2018 – Luglio 2020, vincitore di Assegno di Ricerca per il *“Progetto Strategico di Eccellenza Dipartimentale, Area Cardiometabolica”*, presso il Laboratorio di Epatologia e Gastroenterologia Molecolare, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Elisabetta Bugianesi.
- Novembre 2020 – Giugno 2021, vincitore Borsa di Studio per il progetto *“Meccanismi cellulari e molecolari di danno epatico in pazienti con Non Alcoholic Steato Hepatitis (NASH): creazione di una coorte di studio”*, presso il Laboratorio di Epatologia e Gastroenterologia Molecolare, SC Gastroenterologia U, A.O.U. Città della Salute e della Scienza di Torino, Responsabile Scientifico Prof.ssa Elisabetta Bugianesi.
- Da Agosto 2021 – Dicembre 2021, vincitore Borsa di Studio per il progetto *“Developing a model of care for risk stratification and management of diabetic patients”*, presso il Laboratorio di Epatologia e Gastroenterologia Molecolare, Dipartimento di Scienze

Mediche, Università degli Studi di Torino, Responsabile Scientifico Prof.ssa Elisabetta Bugianesi.

- Da Dicembre 2022, Ricercatore a tempo determinato tipo a (RTDa) presso il Laboratorio di Epatologia e Gastroenterologia Molecolare, Dipartimento di Scienze Mediche, Università degli Studi di Torino.

Attività di ricerca

- Sviluppo di nuovi test sierologici per l'identificazione delle diverse fasi della storia naturale dell'infezione cronica da HBV, per il monitoraggio dei pazienti in terapia con analoghi nucleos(t)idici e per la predizione di infezione occulta in soggetti con marcatori di pregressa esposizione ad HBV (partecipazione a gruppi di lavoro internazionali);
- Studio di marcatori virologici, immunologici ed epigenetici per la predizione della risposta a terapia con interferone in pazienti con infezione da HDV;
- Sviluppo di metodiche di biologia molecolare (ddPCR) per la ricerca di acidi nucleici virali in circolo e nel tessuto epatico;
- Validazione di marcatori non-invasivi di NASH e di fibrosi epatica in pazienti con NAFLD. Validazione di tecniche di immagine (CAP, elastografia epatica, RNM) per la diagnosi non invasiva di NASH e di fibrosi epatica;
- Studio di biomarcatori circolanti (marcatori sierologici ed epigenetici) per la stratificazione del rischio di insorgenza di epatocarcinoma (HCC) in pazienti con epatopatia cronica/cirrosi e studio di biomarcatori prognostici per la predizione dell'outcome clinico e risposta a terapia in pazienti con diagnosi di HCC;
- Studio dei meccanismi di regolazione della permeabilità intestinale e relativi marcatori sierici e fecali responsabili dell'insorgenza e progressione delle malattie infiammatorie intestinali (IBD) e patologie funzionali (IBS);
- Analisi di profili di citochine e chemochine per la personalizzazione della terapia con farmaci biotecnologici in pazienti con IBD.

Partecipazione a progetti di ricerca nazionali e internazionali

Dal 2010 partecipa come collaboratore in progetti di ricerca finanziati su bandi competitivi nazionali ed internazionali per quanto riguarda le attività di laboratorio (stoccaggio e gestione della biobanca del laboratorio; analisi dei campioni biologici), la raccolta dei dati clinici e loro inserimento in database complessi, l'elaborazione statistica dei dati, la stesura di report per la rendicontazione scientifica, la stesura di abstract e poster per la partecipazione a congressi nazionali e internazionali, la stesura di lavori scientifici. Inoltre, risulta sperimentatore principale di progetti di ricerca conto terzi e ha partecipato come collaboratore a numerosi progetti di ricerca locale (ex 60%).

| Titolo del progetto | Sperimentatore Principale |
|---|---|
| Progetti Europei | |
| EPOS: Elucidating Pathways of Steatohepatitis (EU H2020 Program Grant Agreement 634413) | Chief Investigator: Quentin M. Anstee National Clinical Lead: Elisabetta Bugianesi |
| LITMUS: Liver Investigation Testing Marker Utility in Steatohepatitis (EU/EFPIA IMI2 Grant agreement 777377) | Chief Investigator: Quentin M. Anstee National Clinical Lead: Elisabetta Bugianesi |
| Progetti Nazionali | |
| Burden of hepatitis D Virus (HDV) infection in Italy: a prospective/observational multicenter study to define | PI: Mario Rizzetto Co-PI: Gian Paolo Caviglia |

| | |
|---|---|
| demographic, clinical and virological features (HDV Describe; IN-IT-980-6382) | |
| Network Delta piemontese-valdostano per la diagnosi e il management dei pazienti affetti da epatopatia da virus HDV (Gilead Fellowship Program 2022) | PI: Alessia Ciancio Co-PI: Gian Paolo Caviglia Co-PI: Antonella Olivero |
| Impatto del sequenziamento completo dell'esoma sulla gestione clinica del paziente con steatosi epatica non alcolica e malattia epatica criptogenetica (Ricerca Finalizzata RF-2016-02364358) | PI: Luca Valenti (UNIMI) Co-investigator: Elisabetta Bugianesi |
| Progetto Strategico di Eccellenza Dipartimentale (Project n. D15D18000410001) | PI: Franco Veglio |
| Call Fast Track COVID -19 by Area Science Park: Genomic biomarkers for vitamin D response in patients with Covid-19 and IBD | PI: Sharmila Fagoonee (CNR) |
| Progetti di Ricerca Locale | |
| Creazione della BioBanca IBD per la ricerca biomedica sulle malattie infiammatorie croniche intestinali (Fondazione CRT, RF=2015.2643) | PI: Chiara Rosso |
| Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): role in the pathogenesis and progression of Inflammatory Bowel Diseases (Fondazione Cariplo, Ricerca biomedica condotta da giovani ricercatori 2020) | PI: Cristina Travelli (UNIPV) |
| Progetti di ricerca conto terzi | |
| Novel quantitative serological assays (HBcAg and Anti-HBc IgG) in the management of chronic hepatitis B infection" (CMD REF 01-10-02517) | PI: Gian Paolo Caviglia |
| Clinical role of Glypican 3 as a serum-based marker for early detection of HCC | PI: Gian Paolo Caviglia |
| A case-control study to investigate the ability of serum Glypican-3 to discriminate between patients with HCC and benign liver disease induced by dysmetabolic liver disease (NAFLD) | PI: Gian Paolo Caviglia |

Attività di tutoraggio

Attività di tutoraggio in laboratorio rivolta agli studenti del corso di Laurea Magistrale in Biotecnologie Mediche; supporto all'analisi dei dati e alla stesura del lavoro di tesi agli studenti del corso di Laurea in Medicina e Chirurgia, Biotecnologie Mediche, e specializzandi della Scuola di Specializzazione in Malattie dell'Apparato Digerente.

Corsi di formazione professionale e convegni

- Partecipazione a 26 corsi di formazione professionale, 9 dei quali in qualità di relatore, e 2 in qualità di organizzatore
- Partecipazione a 28 convegni nazionali e internazionali (3 comunicazioni orali e 20 poster)

Società Scientifiche

Membro Associazione Italiana Studio Fegato (AISF) dal 2019

Membro Board Vironet C & Delta dal 2022: HDV RNA Validation Board.

Attività di referaggio

Attività di referaggio di Progetti di Ricerca:

- National Research Foundation of Ukraine (NRFU) (2020)

Membro Comitato Editoriale delle seguenti riviste scientifiche:

- Frontiers in Medicine (dal 2022)
- Diagnostics (dal 2021)
- BioMed Research International (dal 2021)
- Current Oncology (dal 2021)
- Journal of Clinical Medicine (dal 2021)
- World Journal of Hepatology (dal 2021)
- Minerva Biotecnologica (dal 2020)

Guest Editor:

- Biology. Special Issue: Advances in Chronic Liver Disease: From pathophysiology to Clinical Practice (2022)
- Journal of Clinical Medicine. Special Issue: Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice (2021)
- Biology. Special Issue: Chronic Hepatitis C: Pathophysiology and Clinical Issues (2020)
- Journal of Clinical Medicine. Special Issue: Translating Immunology into Therapeutic Concepts for Inflammatory Bowel Disease (2020)
- Minerva Biotecnologica. Special Issue: Non-invasive biomarkers for the detection of gastrointestinal cancers (2019)

Topic Editor:

- Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice (2022)

Attività di referaggio per le seguenti riviste scientifiche:

- World Journal of Gastroenterology; Gastrointestinal Disorders; Journal of Medical Virology; BioMed Research International; Laboratory Medicine; Clinical Microbiology and Infection; Disease Markers; Journal of Dermatological Treatment; Liver International; Minerva Medica; Pathogens; Journal of Clinical Medicine; International Journal of Molecular Sciences; Alimentary Pharmacology & Therapeutics; Journal of Viral Hepatitis; Cancers; Diagnostics; Journal of Clinical and Laboratory Analysis; Leukemia & Lymphoma; Minerva Gastroenterology; Molecules; World Journal of Hepatology; Annals of Hepatology; Drug & Therapy Perspectives; Vaccines; Life; Arab Journal of Gastroenterology; World Journal of Gastroenterology; Hepatobiliary & Pancreatic Diseases International; Cancer Biomarkers; BMC Gastroenterology; Journal of Personalized Medicine; JAMA.

Pubblicazioni

1. Armandi A, **Caviglia GP**, Abdulle A, Rosso C, Gjini K, Castelnuovo G, Guariglia M, Perez Diaz del Campo N, D'Amato D, Ribaldone DG, Saracco GM, Bugianesi E. Prognostic Value of Simple

- Non-Invasive Tests for the Risk Stratification of Incident Hepatocellular Carcinoma in Cirrhotic Individuals with Non-Alcoholic Fatty Liver Disease. *Cancers*. 2023;15(6):1659. [IF=6.575](#)
2. Castelnuovo G, Perez-Diaz-Del-Campo N, Guariglia M, Poggiolini I, Armandi A, Rosso C, **Caviglia GP**, Bugianesi E. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease. *Minerva Gastroenterol (Torino)*. 2023 Mar 9. doi: 10.23736/S2724-5985.23.03361-2. In press. [IF=3.186](#)
 3. D'Ascenzo F, Bruno F, Iannaccone M, Testa G, De Filippo O, Giannino G, **Caviglia GP**, Bernstein CN, De Ferrari GM, Bugianesi E, Armandi A, Ribaldone DG. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: A systematic review with meta-analysis. *Int J Cardiol*. 2023;378:96-104. [IF=4.039](#)
 4. **Caviglia GP**, Ribaldone DG, Fagoonee S. Novelties on non-invasive biomarkers for the assessment of intestinal permeability and gut barrier integrity in patients with inflammatory bowel diseases. *Minerva Gastroenterol (Torino)*. 2023;69(1):1-3. [IF=3.186](#)
 5. Colombo G, **Caviglia GP**, Ravera A, Tribocco E, Frara S, Rosso C, Travelli C, Genazzani AA, Ribaldone DG. NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease. *Front Med (Lausanne)*. 2023;10:1116862. [IF=5.058](#)
 6. Francavilla A, Ferrero G, Pardini B, Tarallo S, Zanatto L, **Caviglia GP**, Sieri S, Grioni S, Francescato G, Stalla F, Guiotto C, Crocella L, Astegiano M, Bruno M, Calvo PL, Vineis P, Ribaldone DG, Naccarati A. Gluten-free diet affects fecal small non-coding RNA profiles and microbiome composition in celiac disease supporting a host-gut microbiota crosstalk. *Gut Microbes*. 2023;15(1):2172955. [IF=9.434](#)
 7. Armandi A, Rosso C, Younes R, Leeming DJ, Karsdal MA, **Caviglia GP**, Pérez-Diaz-Del-Campo N, D'Amato D, Abdulle A, Nicolosi A, Castelnuovo G, Saracco GM, Ribaldone DG, Bugianesi E. Cross-Sectional and Longitudinal Performance of Non-Invasive Tests of Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *J Clin Med*. 2023;12(2):650. [IF=4.964](#)
 8. **Caviglia GP**, Garrone A, Bertolino C, Vanni R, Bretto E, Poshnjari A, Tribocco E, Frara S, Armandi A, Astegiano M, Saracco GM, Bertolusso L, Ribaldone DG. Epidemiology of Inflammatory Bowel Diseases: A Population Study in a Healthcare District of North-West Italy. *J Clin Med*. 2023;12(2):641. [IF=4.964](#)
 9. Armandi A, Colombo G, Rosso C, **Caviglia GP**, Olivero A, Abate ML, Guariglia M, Perez Diaz Del Campo N, Castelnuovo G, Ribaldone DG, Saracco GM, Genazzani AA, Bugianesi E. The Predictive Role of Extracellular NAPRT for the Detection of Advanced Fibrosis in Biopsy-Proven Non-Alcoholic Fatty Liver Disease. *Int J Mol Sci*. 2023;24(2):1172. [IF=6.208](#)
 10. Ciancio A, Ribaldone DG, Spertino M, Risso A, Ferrarotti D, **Caviglia GP**, Carucci P, Gaia S, Rolle E, Sacco M, Saracco GM. Who Should Not Be Surveilled for HCC Development after Successful Therapy with DAAS in Advanced Chronic Hepatitis C? Results of a Long-Term Prospective Study. *Biomedicines*. 2023;11(1):166. [IF=4.757](#)

11. **Caviglia GP**, Abate ML, Troshina G, Carucci P, Rolle E, Risso A, Burlone ME, Albè A, Crevola M, Musso EC, Rosso C, Armandi A, Olivero A, Minisini R, Saracco GM, Bugianesi E, Pirisi M, Ciancio A, Gaia S. Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development. *Biology (Basel)*. 2023;12(1):94. [IF=5.168](#)
12. De Nicolò A, Cusato J, Bezzio C, Saibeni S, Venero M, Disabato M, **Caviglia GP**, Ianniello A, Manca A, D'Avolio A, Ribaldone DG. Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease. *Nutrients*. 2022;15(1):169. [IF=6.706](#)
13. Perez-Diaz-Del-Campo N, Castelnuovo G, **Caviglia GP**, Armandi A, Rosso C, Bugianesi E. Role of Circadian Clock on the Pathogenesis and Lifestyle Management in Non-Alcoholic Fatty Liver Disease. *Nutrients*. 2022;14(23):5053. [IF=6.706](#)
14. Rosso C, Demelas C, Agostini G, Abate ML, Venero M, **Caviglia GP**, D'Amato D, Armandi A, Tapparo M, Guariglia M, Troshina G, Massano A, Olivero A, Nicolosi A, Zannetti A, Pellicano R, Ciancio A, Saracco GM, Ribaldone DG, Bugianesi E, Fagoonee S. Expression of SARS-Cov-2 Entry Factors in Patients with Chronic Hepatitis. *Viruses*. 2022;14(11):2397. [IF=5.818](#)
15. Fornaro R, Actis GC, **Caviglia GP**, et al. Inflammatory Bowel Disease: Role of Vagus Nerve Stimulation. *J Clin Med*. 2022;11:5690. [IF=4.964](#)
16. Nicolosi A, Gaia S, Risso A, et al. Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma. *Minerva Gastroenterol*. 2022;68(4):378-386. [IF=3.186](#)
17. **Caviglia GP**, Mineo CA, Rosso C, et al. Predictive Factors of Surgical Recurrence in Patients with Crohn's Disease on Long-Term Follow-Up: A Focus on Histology. *J Clin Med*. 2022;11:5043. [IF=4.964](#)
18. **Caviglia GP**, Ciancio A, Rizzetto M. A Review of HDV Infection. *Viruses*. 2022;14:1749. [IF=5.818](#)
19. Armandi A, Rosso C, Troshina G, et al. Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals. *Biology*. 2022;11:1160. [IF=5.168](#)
20. **Caviglia GP**, Nicolosi A, Abate ML, et al. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. *Curr Oncol*. 2022;29:5457-5465. [IF=3.109](#)
21. Saponaro C, Sabatini S, Gaggini M, et al. Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals. *Liver Int*. 2022;42:2418-2427. [IF=8.754](#)
22. Olivero A, Rosso C, Ciancio A, et al. Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification. *Biomedicines*. 2022;10:792. [IF=4.757](#)
23. Cusato J, Boglione L, De Nicolò A, et al. Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy. *Pharmaceuticals*. 2022;15:355. [IF=5.215](#)
24. Ribaldone DG, **Caviglia GP**, Gaia S, et al. Effect of COVID-19 Pandemic on Hepatocellular Carcinoma Diagnosis: Results from a Tertiary Care Center in North-West Italy. *Curr Oncol*. 2022;29:1422-1429. [IF=3.109](#)
25. Nicolosi A, Pellicano R, **Caviglia GP**. Surveillance of cirrhotic patients using the protein induced

- by vitamin K absence or antagonist II (PIVKA-II). *Minerva Med.* 2022;113:106-108. [IF=5.580](#)
26. Armandi A, Rosso C, Nicolosi A, et al. Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. *J Clin Med.* 2022;11:635. [IF=4.964](#)
 27. **Caviglia GP**, Troshina G, Santaniello U, et al. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. *Cancers.* 2022;14:828. [IF=6.575](#)
 28. Rosso C, Aaron AA, Armandi A, et al. Inflammatory Bowel Disease Nurse-Practical Messages. *Nurs Rep.* 2021;11:229-241. [IF=0](#)
 29. Cusato J, Bertani L, Antonucci M, et al. Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn's Disease: A Pilot Study. *Pharmaceuticals.* 2021;14:1230. [IF=5.215](#)
 30. **Caviglia GP**, Zorzi A, Rizzetto M, et al. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. *Diagnostics.* 2021;11:2185. [IF=3.992](#)
 31. Armandi A, Rosso C, **Caviglia GP**, et al. The Impact of Dysmetabolic Sarcopenia Among Insulin Sensitive Tissues: A Narrative Review. *Front Endocrinol.* 2021;12:716533. [IF=6.055](#)
 32. **Caviglia GP**, De Blasio F, Venero M, et al. Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. *J Clin Med.* 2021;10:4961. [IF=4.964](#)
 33. Francavilla A, Gagliardi A, Piaggieschi G, et al. Faecal miRNA profiles associated with age, sex, BMI, and lifestyle habits in healthy individuals. *Sci Rep.* 2021;11:20645. [IF=4.996](#)
 34. Ponzio P, Campion D, Rizzo M, et al. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function. *Dig Liver Dis.* 2021;54:1101-1108. [IF=5.165](#)
 35. **Caviglia GP**, Martini S, Ciancio A, et al. The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease. *J Adv Res.* 2021;33:183-187. [IF=12.822](#)
 36. Ditto MC, Parisi S, Landolfi G, et al. Intestinal microbiota changes induced by TNF-inhibitors in IBD related spondyloarthritis. *RMD Open.* 2021;7:e001755. [IF=5.806](#)
 37. Ribaldone DG, Tribocco E, Rosso C, et al. Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. *J Clin Med.* 2021;10(15):3387. [IF=4.964](#)
 38. **Caviglia GP**, Troshina Y, Garro E, et al. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. *J Clin Med.* 2021;10:3308. [IF=4.964](#)
 39. **Caviglia GP**, Martini G, Armandi A, et al. Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease. *J Clin Med.* 2021;10:3257. [IF=4.964](#)
 40. Ribaldone DG, Zurlo C, Fagoonee S, et al. A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. *Life.* 2021;11:650. [IF=3.251](#)

41. Younes R*, **Caviglia GP***, Govaere O, et al. Long-term Outcomes and Predictive Ability by Simple Non Invasive Scoring Systems (NSS) in Patients with Non-Alcoholic Fatty Liver Disease. *J Hepatol.* 2021; 75:786-794. [IF=30.083](#)
42. **Caviglia GP**, Armandi A, Rosso C, et al. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. *Cancers.* 2021;13:2305. [IF=6.575](#)
43. Rosso C, Armandi A, Nicolosi A, et al. Role of triglycerides to high-density lipoprotein cholesterol ratio in non-alcoholic fatty liver disease progression. *Minerva Gastroenterol.* 2021;67:405-406. [IF=3.186](#)
44. Stalla F, Armandi A, Marinoni C, et al. Chronic hepatitis B virus infection and fibrosis: novel non-invasive approaches for diagnosis and risk stratification. *Minerva Gastroenterol.* 2022;68:306-318. [IF=3.186](#)
45. Armandi A, Rosso C, **Caviglia GP**, et al. Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. *Metabolites.* 2021;11:155. [IF=5.581](#)
46. **Caviglia GP**, Abate ML, Rolle E, et al. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. *Biology.* 2021;10:215. [IF=5.168](#)
47. Armandi A, Pellicano R, **Caviglia GP**. Tight junction regulation in celiac disease: role of larazotide acetate. *Minerva Gastroenterol.* 2022;68:4-6. [IF=3.186](#)
48. Baima G, Massano A, Squillace E, et al. Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review. *Oral Dis.* 2022;28:1029-1041. [IF=4.068](#)
49. Vizio B, Bosco O, David E, et al. Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma. *Int J Mol Sci.* 2021;22:1818. [IF=6.208](#)
50. Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? *Gut.* 2022;71:382-390. [IF=31.793](#)
51. **Caviglia GP**, Armandi A, Rosso C, et al. Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. *Diagnostics.* 2021;11:187. [IF=3.992](#)
52. Martelletti C, Armandi A, **Caviglia GP**, et al. Elastography for characterization of focal liver lesions: current evidence and future perspectives. *Minerva Gastroenterol Dietol.* 2021;67:196-208. [IF=3.186](#)
53. Brunetto MR, Carey I, Maasoumy B, et al. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. *Aliment Pharmacol Ther.* 2021;53:733-744. [IF=9.524](#)
54. Rosso C, **Caviglia GP**, Armandi A, et al. Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease? *Clin Res Hepatol Gastroenterol.* 2021;45:101611. [IF=3.189](#)
55. **Caviglia GP**, Rosso C. Is the pattern of liver disease etiology changing in China? *Minerva Med.* 2021;112:521. [IF=5.580](#)
56. Vernerio M, De Blasio F, Ribaldone DG, et al. The Usefulness of Microencapsulated Sodium

- Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. *J Clin Med.* 2020;9:E3941. [IF=4.241](#)
57. Ribaldone DG, Venero M, **Caviglia GP**. Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signalling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuate progression of oxazolone-induced colitis. *Fundam Clin Pharmacol.* 2021;35:141-142. [IF=2.747](#)
58. **Caviglia GP**, Rosso C, Armandi A, et al. Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P. *Int J Mol Sci.* 2020;21:8838. [IF=5.923](#)
59. **Caviglia GP**, Ciruolo M, Abate ML, et al. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. *Cancers.* 2020;12:3218. [IF=6.639](#)
60. Armandi A, Rosso C, Ribaldone DG, et al. Moving towards core antigen for the management of patients with overt and occult HBV infection. *Panminerva Med.* 2021;63:499-507. [IF=5.268](#)
61. **Caviglia GP**, Ciruolo M, Olivero A, et al. Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma. *Cancers.* 2020;12:E2776. [IF=6.639](#)
62. **Caviglia GP**. Role of immunoglobulin indexes in patients with chronic hepatitis B. *Minerva Med.* 2020;111:382-383. [IF=4.806](#)
63. Rosso C, **Caviglia GP**, Younes R, et al. Molecular mechanisms of hepatic fibrosis in chronic liver diseases. *Minerva Biotechnol.* 2020;32,121-127. [IF=3.028](#)
64. **Caviglia GP**, Tucci A, Pellicano R, et al. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. *J Clin Med.* 2020;9:2353. [IF=4.241](#)
65. Carli E, **Caviglia GP**, Pellicano R, et al. Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. *Medicina.* 2020;56:E285. [IF=2.430](#)
66. Younes R, Govaere O, Petta S, et al. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. *Am J Gastroenterol.* 2020;115:1289-1292. [IF=10.864](#)
67. Bertani L, **Caviglia GP**, Antonioli L, et al. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. *J Clin Med.* 2020;9:1323. [IF=4.241](#)
68. Yoshida K, Desbiolles A, Feldman SF, et al. Assay for Hepatitis B Core-related Antigen Identify Patients With High Viral Load: Systematic Review and Meta-analysis of Individual Participant Data. *Clin Gastroenterol Hepatol.* 2021;19:46-60.e8. [IF=13.576](#)
69. Colombo G, Clemente N, Zito A, et al. Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis. *J Mol Med.* 2020;98:595-612. [IF=4.599](#)
70. **Caviglia GP**, Rosso C, Stalla F, et al. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. *J Clin Med.* 2020;9:800. [IF=4.241](#)
71. **Caviglia GP**, Rizzetto M. Treatment of hepatitis D: an unmet medical need. *Clin Microbiol Infect* 2020;26:824-827. [IF=8.067](#)

72. Ribaldone DG, **Caviglia GP**, Pellicano R, et al. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. *Rev Esp Enferm Dig.* 2020;112:195-200. [IF=2.086](#)
73. **Caviglia GP**, Olivero A, Ciancio A, et al. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. *Diagn Microbiol Infect Dis.* 2020;96:114985. [IF=2.803](#)
74. **Caviglia GP**. Edaravone and MAPK pathway: the key role of gut permeability. *Minerva Med.* 2020;111:181. [IF=4.806](#)
75. Pellicano R, Ribaldone DG, **Caviglia GP**. Strategies for Helicobacter pylori eradication in the year 2020. *Saudi J Gastroenterol.* 2020;26:63-65. [IF=2.485](#)
76. Petrini E, **Caviglia GP**, Pellicano R, et al. Risk of drug interactions and prescription appropriateness in elderly patients. *Ir J Med Sci* 2019;189:953-959. [IF=1.100](#)
77. Ribaldone DG, **Caviglia GP**, Pellicano R, et al. Adalimumab versus azathioprine to halt the progression of bowel damage in Crohn's disease: application of Lémann Index. *Scand J Gastroenterol.* 2019;54:1339-1345. [IF=2.130](#)
78. Ribaldone DG, **Caviglia GP**, Abdule A, et al. Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease. *J Clin Med.* 2019;8:1646. [IF=3.303](#)
79. Khodjaeva M, Ibadullaeva N, Khikmatullaeva A, et al. The medical impact of hepatitis D virus infection in Uzbekistan. *Liver Int.* 2019;39:2077-2081. [IF=5.175](#)
80. Ribaldone DG, Adriani A, **Caviglia GP**, et al. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. *Medicina.* 2019;55:441. [IF=1.205](#)
81. Alessandria C, **Caviglia GP**, Campion D, et al. HLA-DQ Genotyping, Duodenal Histology, and Response to Exclusion Diet in Autistic Children With Gastrointestinal Symptoms. *J Pediatr Gastroenterol Nutr.* 2019;69:39-44. [IF=2.937](#)
82. Rosso C, **Caviglia GP**, Ciruolo M, et al. Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study. *Minerva Med.* 2019; 110:401-409. [IF=3.031](#)
83. Ribaldone DG, Pellicano R, Vernerio M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. *Scand J Gastroenterol.* 2019;54:407-413. [IF=2.130](#)
84. **Caviglia GP**, Dughera F, Ribaldone DG, et al. Serum zonulin in patients with inflammatory bowel disease: a pilot study. *Minerva Med.* 2019;110:95-100. [IF=3.031](#)
85. **Caviglia GP**, Olivero A, Ngatchou D, Saracco GM, Smedile A. Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. *Minerva Gastroenterol Dietol.* 2019;65:77-78. [IF=0](#)
86. **Caviglia GP**, Pellicano R, Saracco GM, et al. Hepatitis B Core-Related Antigen: A Serum Biomarker for Intrahepatic Covalently-Closed-Circular DNA. *Clin Lab.* 2018;64:411-412. [IF=0.955](#)
87. Marinoni C, Ribaldone DG, Rosso C, et al. Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test. *Minerva Biotechnol.* 2019;31:100-107. [IF=1.178](#)

88. **Caviglia GP**, Rosso C, Davide DG, et al. Physiopathology of intestinal barrier and the role of zonulin. *Minerva Biotechnol.* 2019;31:83-92. [IF=1.178](#)
89. Campion D, Tucci A, Ponzio P, et al. Non-invasive biomarkers for the detection of hepatocellular carcinoma. *Minerva Biotechnol.* 2019;31:11-22. [IF=1.178](#)
90. **Caviglia GP**, Olivero A, Smedile A. Reply to: "Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition". *J Hepatol.* 2019;70:559-560. [IF=20.582](#)
91. **Caviglia GP**, Tandoi F, Olivero A, et al. Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors. *J Hepatol.* 2019;70:793-795. [IF=20.582](#)
92. **Caviglia GP**, Ribaldone DG, Abate ML, et al. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. *Scand J Gastroenterol.* 2018;53:734-740. [IF=2.152](#)
93. **Caviglia GP**, Fagoonee S. Comment on "Changes in acute viral hepatitis epidemiology in the Turkish adult population: A multicenter study". *Turk J Gastroenterol.* 2018;29:719. [IF=1.107](#)
94. **Caviglia GP**, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. *J Hepatol.* 2018;69:301-307. [IF=18.946](#)
95. Ribaldone DG, Mazzucco D, Fagoonee S, et al. Management of *Helicobacter pylori* in Piedmont, Italy. *Minerva Gastroenterol Dietol.* 2018;64:235-250. [IF=0](#)
96. **Caviglia GP**, Ribaldone DG, Rosso C, et al. Fecal calprotectin: beyond intestinal organic diseases. *Panminerva Med.* 2018;60:29-34. [IF=2.186](#)
97. Ricco G, Cavallone D, Cosma C, et al. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. *Cancer Biomark.* 2018;21:603-612. [IF=2.859](#)
98. Ribaldone DG, Vernerio M, Saracco GM, et al. The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. *Scand J Gastroenterol.* 2018;53:141-146. [IF=2.152](#)
99. Rosso C, **Caviglia GP**, Fagoonee S, et al. Basic and clinical aspects of resistin. *Minerva Biotechnol.* 2018;30:75-81. [IF=0.596](#)
100. **Caviglia GP**, Olivero A, Rosso C, et al. Laboratory evidence of *Helicobacter* species infection in hepatocellular carcinoma. *Minerva Biotechnol.* 2018;30:88-93. [IF=0.596](#)
101. **Caviglia GP**, Noviello D, Pellicano R, et al. Role of serum hepatitis B core-related antigen in chronic hepatitis B infection. *Minerva Biotechnol.* 2018;30:29-35. [IF=0.596](#)
102. Younes R, Rosso C, Petta S, et al. Usefulness of the index of NASH - ION for the diagnosis of steatohepatitis in patients with non-alcoholic fatty liver: An external validation study. *Liver Int.* 2018;38:715-723. [IF=5.542](#)
103. **Caviglia GP**, Fagoonee S. Role and function of exosomal miR-9-3p in hepatocellular carcinoma. *Minerva Med.* 2018;109:4-6. [IF=2.475](#)
104. **Caviglia GP**, Rosso C, Fagoonee S, et al. Liver fibrosis: the 2017 state of art. *Panminerva Med.* 2017;59:320-331. [IF=2.102](#)
105. **Caviglia GP**, Sguazzini C, Cisarò F, et al. Gastric emptying and related symptoms in patients

treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. *Minerva Med.* 2017;108:489-495. [IF=2.863](#)

106. **Caviglia GP**, Smedile A. Hepatitis B core-related antigen: a novel biomarker for chronic hepatitis B treatment. *Minerva Gastroenterol Dietol.* 2017;63:169-171. [IF=2.475](#)
107. **Caviglia GP**, Abate ML, Gaia S, et al. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II. *Panminerva Med.* 2017;59:283-289. [IF=2.102](#)
108. Castroflorio T, Gambero EF, **Caviglia GP**, et al. Biochemical markers of bone metabolism during early orthodontic tooth movement with aligners. *Angle Orthod.* 2017;87:74-81. [IF=1.592](#)
109. **Caviglia GP**, Bosco C. Helicobacter pylori, gastric cancer and gastric cancer stem cells. *Minerva Biotechnol.* 2017;29:180-187. [IF=0.365](#)
110. Astegiano M, Touscoz GA, **Caviglia GP**, et al. Non-organ-specific autoimmunity in patients suffering from gastric ulcer with and without Helicobacter pylori infection. *Minerva Biotechnol.* 2017;29:109-113. [IF=0.365](#)
111. Bonagura GA, Ribaldone DG, Fagoonee S, et al. Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity ("lymphocytic enterocolitis")? *World J Gastrointest Pathophysiol.* 2016;7:307-313. [IF=0](#)
112. Rosso C, **Caviglia GP**, Pellicano R. Usefulness of fecal calprotectin determination in pediatric intestinal diseases. *Minerva Pediatr.* 2016;68:478-486. [IF=0.764](#)
113. Saracco GM, Evangelista A, Fagoonee S, et al. Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. *World J Gastroenterol.* 2016;22:8187-8193. [IF=3.365](#)
114. **Caviglia GP**, Abate ML, Noviello D, et al. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon- α . *Hepatol Res.* 2017;47:747-754. [IF=3.418](#)
115. **Caviglia GP**, Cabianca L, Fagoonee S, et al. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. *Biochem Med (Zagreb).* 2016;26:114-120. [IF=2.934](#)
116. **Caviglia GP**, Pellicano R. On "Diagnostic value of aberrant gene methylation in stool samples for colorectal cancer or adenomas". *Panminerva Med.* 2016;58:102. [IF=1.698](#)
117. **Caviglia GP**. L-arginine, apoptosis and gastric cancer: any role for Helicobacter pylori? *Panminerva Med.* 2015;57:217. [IF=1.600](#)
118. Italian Association for the Study of the Liver (AISF); Italian Association for the Study of the Liver AISF. AISF position paper on liver disease and pregnancy. *Dig Liver Dis.* 2016;48:120-137. [IF=3.061](#)
119. Ribaldone DG, Fagoonee S, Astegiano M, et al. Coxib's Safety in Patients with Inflammatory Bowel Diseases: A Meta-analysis. *Pain Physician.* 2015;18:599-607. [IF=3.407](#)
120. Rosso C*, **Caviglia GP***, Abate ML, et al. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. *Dig Liver Dis.* 2016;48:55-61. [IF=3.061](#)
121. Rosso C, Mezzabotta L, Gaggini M, et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. *Hepatology.* 2016;63:107-116.

IF=13.246

122. **Caviglia GP**, Rosso C, Fagoonee S, et al. Endocrine manifestations of chronic HCV infection. *Minerva Endocrinol.* 2015;40:321-329. IF=1.118
123. **Caviglia GP**, Pellicano R. Serum Cytokeratin-18 Levels for Liver Fibrosis Prediction. *Hepat Mon.* 2015;15:e30853. IF=1.932
124. **Caviglia GP**, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. *Hepatol Res.* 2016;46:E130-135. IF=2.602
125. Greco A*, **Caviglia GP***, Brignolo P, et al. Glucose breath test and Crohn's disease: Diagnosis of small intestinal bacterial overgrowth and evaluation of therapeutic response. *Scand J Gastroenterol.* 2015;50:1376-1381. IF=2.199
126. **Caviglia GP**, Fagoonee S, Pellicano R. Re: El-Garem et al.: Seminal Helicobacter pylori Treatment Improves Sperm Motility in Infertile Asthenozoospermic Men (*Urology* 2014;84:1347-1350). *Urology.* 2015;85:1217. IF=2.187
127. Petrini E, **Caviglia GP**, Abate ML, et al. MicroRNAs in HBV-related hepatocellular carcinoma: functions and potential clinical applications. *Panminerva Med.* 2015;57:201-209. IF=1.600
128. **Caviglia GP**, Pellicano R, Astegiano M. Reply to: Diagnostic power of fecal calprotectin in inflammatory and functional intestinal disorders. *Scand J Gastroenterol.* 2015;50:623-4. IF=2.361
129. **Caviglia GP**, Pantaleoni S, Touscoz GA, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. *Scand J Gastroenterol.* 2014;49:1419-1424. IF=2.361
130. **Caviglia GP**, Sciacca C, Abate ML, et al. Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. *J Gastroenterol Hepatol.* 2015;30:742-747. IF=3.322
131. **Caviglia GP**, Abate ML, Pellicano R, et al. Chronic hepatitis B therapy: available drugs and treatment guidelines. *Minerva Gastroenterol Dietol.* 2015;61:61-70. IF=0
132. Rosso C, Abate ML, Ciancio A, et al. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. *World J Gastroenterol.* 2014;20:13146-13152. IF=2.369
133. Tandoi F*, **Caviglia GP***, Pittaluga F, et al. Prediction of occult hepatitis B virus infection in liver transplant donors through hepatitis B virus blood markers. *Dig Liver Dis.* 2014;46:1020-1024. IF=2.963
134. De Nicolò A, Boglione L, Ciancio A, et al. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner. *Antiviral Res.* 2014;109:7-14. IF=3.938
135. Burdino E, Ruggiero T, Proietti A, et al. Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays. *J Clin Virol.* 2014;60:341-346. IF=3.016
136. **Caviglia GP**, Touscoz GA, Smedile A, et al. Noninvasive assessment of liver fibrosis: key messages for clinicians. *Pol Arch Med Wewn.* 2014;124:329-335. IF=2.212

137. **Caviglia GP**, Ciancio A, Rosso C, et al. Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment. *Ann Hepatol.* 2013 Jan-2014;13:91-97. IF=2.193
138. D'Avolio A, De Nicolò A, Cusato J, et al. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients. *Antiviral Res.* 2013;100:114-119. IF=3.434
139. Petta S, Rosso C, Leung R, et al. Effects of IL28B rs12979860 CC Genotype on Metabolic Profile and Sustained Virologic Response in Patients With Genotype 1 Chronic Hepatitis C. *Clinic Gastroenterol Hepatol.* 2013;11:311-317. IF=6.534
140. **Caviglia GP**, Abate ML, Manzini P, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. *Hepat Mon.* 2012;12:e7292. IF=1.245
141. D'Avolio A, Ciancio A, Siccardi M, et al. Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. *Ther Drug Monit.* 2012;34:722-728. IF=2.234
142. Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. *J Hepatol.* 2010;53:834-840. IF=9.334
143. Santovito A, Cervella P, Selvaggi A, et al. DAT1 VNTR polymorphisms in a European and an African population: identification of a new allele. *Hum Biol.* 2008;80:191-198. IF=0.807

Impact factor totale: 653.307

Impact factor medio: 4.569

Torino, 25/03/2023

